June 4 (Reuters) - Sierra Oncology Inc SRRA.O :
* SIERRA ANNOUNCES FDA REGULATORY CLARITY FOR MOMELOTINIB & DESIGN OF THE MOMENTUM PHASE 3 CLINICAL TRIAL
* SIERRA ANNOUNCES FDA REGULATORY CLARITY FOR MOMELOTINIB & DESIGN OF THE MOMENTUM PHASE 3 CLINICAL TRIAL
* SIERRA ONCOLOGY INC - MOMENTUM PHASE 3 CLINICAL TRIAL PLANNED FOR LAUNCH IN Q4 2019; TOPLINE EFFICACY DATA ANTICIPATED IN Q4 2021
* SIERRA ONCOLOGY INC - STUDY POWERED 99% ON PRIMARY ENDPOINT OF SYMPTOMATIC BENEFIT; >90% POWERED ON SECONDARY ENDPOINTS OF ANEMIA BENEFIT AND SPLEEN REDUCTION